XBiotech Inc.

Company Overview

Business Model: XBiotech Inc. is a biopharmaceutical company focused on the discovery and development of True Human™ monoclonal antibodies for a range of diseases. Its proprietary technology enables the isolation and cloning of antibodies from human donors who exhibit natural immune responses, differentiating its product candidates from animal-derived or engineered antibodies prevalent in the market. XBiotech operates as a fully integrated biopharmaceutical developer, managing discovery, manufacturing, and clinical trial operations from its research campus in Austin, Texas. The Company's primary therapeutic focus areas include interleukin-1 alpha (IL-1a) mediated inflammatory diseases and various infectious diseases.

Market Position: XBiotech positions itself uniquely in the $247 billion antibody market by developing True Human™ antibodies, which are derived directly from natural human immune responses, in contrast to all other marketed antibody therapies that are animal-derived and engineered. The Company believes this approach offers the potential for safer, more effective, and faster-to-develop therapeutics. XBiotech is a fully integrated developer, controlling its entire process from discovery to manufacturing and clinical trials, which contributes to cost-effectiveness and efficiency. The Company targets significant unmet medical needs, particularly in IL-1a mediated diseases, which it views as having market potential comparable to anti-TNF therapies.

Recent Strategic Developments:

• IL-1a Asset Sale & Reinvestment: In late 2019, XBiotech Inc. sold a True Human™ antibody therapeutic targeting IL-1a to Janssen Biotech, Inc. for $750 million in cash and up to $600 million in potential milestone payments. This transaction allowed XBiotech Inc. to retain rights to discover and develop new anti-IL-1a antibodies for non-dermatological indications, with Janssen Biotech, Inc. agreeing to assert acquired patents for XBiotech Inc.'s benefit in these areas.
• New IL-1a Pipeline Development: Following the sale, XBiotech Inc. rapidly identified and advanced new IL-1a targeting product candidates into clinical studies across oncology, rheumatology, and neurology. The Company is developing two anti-IL-1a product candidates in parallel.
• Oncology Program (Natrunix™): A randomized, double-blinded, placebo-controlled Phase II clinical study of Natrunix™ in combination with chemotherapy for pancreatic cancer, involving 60 subjects, concluded its last subject visit in February 2024. Preliminary analysis, announced on June 18, 2024, indicated that Natrunix™ treatment led to reduced hospitalization, fewer serious adverse events, longer progression-free survival, and less severe diarrhea compared to placebo. XBiotech Inc. believes this effect may extend to other solid tumors treated with chemotherapy and plans to propose a registration path to the FDA in Q2 2025.
• Rheumatology Program (Natrunix™): A double-blind, placebo-controlled study investigating Natrunix™ for rheumatoid arthritis in combination with methotrexate, enrolling 233 subjects, was completed with findings announced on December 23, 2024. However, the Company determined that widespread improprieties at clinical sites rendered the data uninterpretable, though XBiotech Inc. maintains belief in Natrunix™'s potential for arthritic diseases.
• Neurology Program (Hutrukin): An investigational new drug application for Hutrukin, a True Human™ antibody to reduce brain injury after stroke reperfusion procedures, was filed in 2022. A Phase I study completed in late 2023 demonstrated high bolus doses were safe and well-tolerated, with data analysis completed in Q1 2024. Plans for a Phase II study in stroke in 2024 have been put on hold pending clarification of regulatory paths for the cancer and arthritis programs.
• Infrastructure Expansion: In 2022, XBiotech Inc. completed an expansion of its manufacturing and R&D center, adding new research laboratories and administrative space. In Q1 2024, the Company initiated architectural and engineering plans for a new multi-story 46,000 sq ft R&D facility and a 5,000 sq ft infectious disease research annex, but construction has been indefinitely paused due to regulatory and program setbacks in rheumatology.
• Contract Manufacturing & Services: From 2020 through the end of 2023, XBiotech Inc. utilized its manufacturing technology and facilities to produce drug product and provide clinical trial operations services for a world-leading pharmaceutical company under supply agreements, which have now concluded.

Geographic Footprint: XBiotech Inc.'s headquarters and primary operations are located in Austin, Texas, where it owns a 48-acre research campus housing its R&D and manufacturing facilities. The Company previously had a wholly-owned subsidiary, XBiotech Germany GmbH, which was dissolved in February 2023. Substantially all of the Company's current operations are within the U.S. geographic segment.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 0.0% (No revenue generated)
• Operating Margin: Not applicable (No revenue generated; operating loss was 100% of total operating expenses)
• Net Margin: Not applicable (No revenue generated; net loss was 100% of total operating expenses)

Investment in Growth:

• R&D Expenditure: $37.8 million (88.9% of total operating expenses)
• Capital Expenditures: $1.3 million
• Strategic Investments: In January 2024, XBiotech Inc. entered into a Convertible Loan Agreement with its CEO, John Simard, for $10 million to fund the construction of a new research and development facility.

Business Segment Analysis

IL-1a Therapies

Financial Performance: Research and development expenses, which include costs for IL-1a therapies, increased by 15% to $37.8 million in 2024 from $32.8 million in 2023. This increase was primarily driven by higher salaries and related expenses due to company-wide bonuses and an increase in R&D employees, as well as increased clinical trial and sponsored research costs from a new study initiated in Q2 2023.

• Revenue: Not applicable (product candidates are in development)
• Operating Margin: Not applicable
• Key Growth Drivers: Advancement of Natrunix™ in oncology and rheumatology, and Hutrukin in neurology. The Company believes the positive preliminary findings for Natrunix™ in pancreatic cancer represent a transformative approach to cancer management.

Product Portfolio:

• Natrunix™: A True Human™ antibody targeting IL-1⍺.
  • Oncology (Pancreatic Cancer): Completed a randomized, double-blinded, placebo-controlled Phase II study (60 subjects). Preliminary analysis (June 2024) showed reduced hospitalization, fewer serious adverse events, longer progression-free survival, and less severe diarrhea in Natrunix™-treated patients. The Company plans to propose a registration path to the FDA in Q2 2025.
  • Rheumatology (Rheumatoid Arthritis): Completed a double-blind, placebo-controlled study (233 subjects) in combination with methotrexate. Findings announced in December 2024 were deemed uninterpretable due to widespread improprieties at clinical sites, though the Company maintains belief in its potential.
• Hutrukin: A True Human™ antibody candidate therapeutic to reduce brain injury after stroke reperfusion procedures.
  • Neurology (Stroke): Completed a Phase I study (end of 2023) demonstrating high bolus doses are safe and well-tolerated. Analysis completed in Q1 2024. Phase II study plans are on hold pending regulatory clarity for cancer and arthritis programs.

Market Dynamics: XBiotech Inc. is targeting a significant unmet medical need in blocking IL-1a, which mediates various pathophysiological processes in chronic and acute injury scenarios. The Company views the market potential for IL-1a therapies as comparable to the anti-TNF therapies developed over the past 25 years.

Infectious Disease Pipeline

Financial Performance: Costs associated with the infectious disease pipeline are included within the overall research and development expenses.

• Revenue: Not applicable (product candidates are in development)
• Operating Margin: Not applicable
• Key Growth Drivers: Addressing urgent unmet medical needs for anti-infective antibody therapies, leveraging the True Human™ antibody discovery process to provide potent and targeted immunity.

Product Portfolio:

• Clinical Stage Therapeutic: For methicillin resistant Staphylococcus aureus (MRSA).
• Pre-clinical Stage Therapeutics:
  • Oral delivery antibody therapeutic for colon infection by C. difficile.
  • Injectable therapy for varicella zoster (shingles).
  • Influenza therapy, designed to neutralize all known strains and variants of influenza since the 1918 pandemic.

Market Dynamics: The Company is dedicated to advancing its infectious disease pipeline to address unmet medical needs, particularly in vulnerable populations such as the elderly (waning natural immunity) and young children (developing immunity), or in cases where natural immunity is overwhelmed.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: $0 for the year ended December 31, 2024. In June 2023, XBiotech Inc. repurchased 3,561 common shares at $4.00 per share, totaling $14 thousand, as part of a modified Dutch auction tender offer. Since 2020, the Company has returned $495 million to shareholders through stock repurchases and dividends, including a $420 million tender offer in February 2020.
• Dividend Payments: $0 for the years ended December 31, 2024 and 2023. XBiotech Inc. paid $75 million ($2.50 per share) in dividends in July 2021.
• Dividend Yield: Not applicable for the current period as no dividends were paid.
• Future Capital Return Commitments: The Company currently intends to retain any earnings for future growth and does not expect comparable cash dividends in the foreseeable future.

Balance Sheet Position:

• Cash and Equivalents: $172.7 million as of December 31, 2024, down from $200.0 million as of December 31, 2023.
• Total Debt: $10.3 million as of December 31, 2024, consisting of a $10.0 million convertible loan from a related party (John Simard) and a $0.3 million convertible loan from a third party.
• Net Cash Position: $162.4 million as of December 31, 2024 ($172.7 million cash and equivalents - $10.3 million total debt).
• Credit Rating: Not disclosed.
• Debt Maturity Profile: The $10.0 million convertible loan from John Simard had a contractual maturity date of January 3, 2029, with interest-only payments every six months. This loan was terminated and fully repaid on January 31, 2025, subsequent to the reporting period.

Cash Flow Generation:

• Operating Cash Flow: $(31.0) million used in 2024, compared to $(18.7) million used in 2023. The increase in cash used was primarily due to higher salaries, related expenses, and clinical trial expenses.
• Free Cash Flow: $(32.3) million used in 2024, compared to $(19.1) million used in 2023.
• Cash Conversion Metrics: Not explicitly disclosed.

Operational Excellence

Production & Service Model: XBiotech Inc. is a fully integrated biopharmaceutical company that discovers, develops, manufactures, and manages clinical trial operations for its True Human™ therapeutic antibodies. The Company has developed proprietary manufacturing technology aimed at reducing the cost and time required to launch new product candidates. Its operational philosophy centers on leveraging natural human immunity to create therapeutic products.

Supply Chain Architecture: Key Suppliers & Partners:

• Manufacturing Components: Crucial components for the manufacturing process are acquired from vendors, with few alternate sources, posing a potential supply disruption risk.
• Research Collaboration: South Texas Blood & Tissue Center - Partnered for research and collaboration, likely for procuring blood donations and screening for antibodies.
• Licensing: Lonza Sales AG - Involved in a licensing agreement, indicating a partnership for certain technologies or processes.

Facility Network:

• Manufacturing: XBiotech Inc. owns a 48-acre research campus in Austin, Texas, which includes a combined R&D and manufacturing facility built in 2016. This facility was expanded in 2022 with two new wings for research laboratories and administrative space, enhancing capacity for a larger workforce and multiple drug product production.
• Research & Development: The Austin campus houses state-of-the-art research laboratories. In 2019, a separate facility for infectious disease and animal research (ABSL2 laboratory) was constructed on campus. Plans for a new multi-story 46,000 sq ft R&D facility and a 5,000 sq ft infectious disease research annex were initiated in Q1 2024 but have been indefinitely paused.
• Distribution: Not explicitly detailed, as the Company does not have commercialized products.

Operational Metrics:

• R&D Employees: 89 employees in 2024, up from 79 in 2023.
• Total Employees: 92 full-time employees as of December 31, 2024.

Market Access & Customer Relationships

Go-to-Market Strategy: XBiotech Inc. currently lacks a comprehensive infrastructure for the sales, marketing, and distribution of pharmaceutical drug products. The Company's future strategy for market access will involve either building internal sales, marketing, and managerial capabilities or establishing collaborations with third parties to perform these services.

Customer Portfolio: Enterprise Customers:

• Past Strategic Partnerships: XBiotech Inc. previously had a supply agreement and provided clinical trial operations services for a world-leading pharmaceutical company (Janssen Biotech, Inc. related) from 2020 through the end of 2023. These agreements have concluded.
• Customer Concentration: Not applicable for current product sales as the Company has no commercialized products.

Geographic Revenue Distribution: Not applicable, as the Company currently generates no product revenue. Substantially all of the Company's operations are in the U.S. geographic segment.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The pharmaceutical and biotechnology industry, particularly the antibody market, is highly competitive and has been dominated by antibody therapeutics for the past 25 years, representing a $247 billion market. The development of new drug products is capital-intensive and carries significant risk. The market for therapies blocking IL-1a is considered to have significant unmet medical need and potential, comparable to the anti-TNF therapy market.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors: XBiotech Inc. faces substantial competition from numerous large pharmaceutical and biotechnology companies, as well as academic institutions, government agencies, and other research organizations. These competitors are pursuing or already market products for the disease indications XBiotech Inc. is targeting, utilizing similar or entirely different scientific approaches. Many competitors possess significantly greater financial, technical, and human resources.

Emerging Competitive Threats: The Company operates in an environment where new therapeutics are constantly being developed, which could supplant or expand upon existing standards of care. The competitive landscape is dynamic, and the standard of care for target diseases may evolve as XBiotech Inc.'s product candidates progress through clinical development.

Competitive Response Strategy: XBiotech Inc.'s strategy is to leverage its unique True Human™ antibody discovery technology, believing that the natural immune repertoire of the human body is the greatest untapped resource for new therapeutics. The Company continues to catalogue and develop these True Human™ antibodies to maintain a competitive advantage.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics: The Company faces risks from new laws or regulations in the U.S., Europe, or other jurisdictions that could impact regulatory approvals and commercialization. The regulatory approval processes are lengthy, time-consuming, and unpredictable. Even if approved, product candidates may not achieve adequate market acceptance. XBiotech Inc. operates in a highly competitive environment where others may discover, develop, or commercialize products more successfully. Technology Disruption: There is a risk that XBiotech Inc.'s research programs may not succeed, or that even an effective drug candidate may not be commercially successful due to competitive products, rare disease indications, or lack of market buy-in.

Operational & Execution Risks

Supply Chain Vulnerabilities: XBiotech Inc. relies on vendors for crucial manufacturing components, with few alternate sources, which could lead to supply disruptions. Geographic Concentration: The Company's operations are concentrated in Austin, Texas, making it vulnerable to business disruptions from natural disasters (e.g., earthquakes, floods, fires, extreme weather), infrastructure interruptions (e.g., power outages, telecommunications failures), or public health threats (e.g., epidemics like the coronavirus pandemic). Capacity Constraints: While the Company completed an R&D and manufacturing center expansion in 2022, plans for further facility expansion were indefinitely paused, indicating potential future constraints if rapid growth resumes.

Financial & Regulatory Risks

Market & Financial Risks: XBiotech Inc. expects to incur significant losses for the foreseeable future and has limited opportunities to generate product revenue, potentially never achieving sustained profitability. The Company may require substantial additional capital, which could lead to dilution for existing shareholders, operational restrictions, or relinquishing rights to technologies. Foreign Exchange: The Company is exposed to foreign exchange fluctuations, particularly between the U.S. dollar and the Canadian dollar, which can result in gains or losses. Credit & Liquidity: Future capital requirements are substantial and depend on the progress and costs of R&D, clinical trials, regulatory approvals, and commercialization. Future financing may not be available on acceptable terms or at all. Regulatory & Compliance Risks: The pharmaceutical industry is heavily regulated. Product candidates may cause undesirable side effects, delaying or preventing approval, limiting commercial labels, or leading to negative consequences post-approval. Even with approval, products face ongoing regulatory oversight, including manufacturing compliance (cGMP), advertising restrictions, and potential post-marketing studies or risk management requirements. Non-compliance can result in fines, sanctions, or withdrawal of approval.

Geopolitical & External Risks

Geopolitical Exposure: The transition to new U.S. presidential administrations and changes in policy, such as the implementation of tariffs on imports from Canada (e.g., 25% additional tariff announced February 1, 2025), could materially impact XBiotech Inc.'s macroeconomic operating framework, supply chains, and overall financial performance.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• True Human™ Monoclonal Antibodies: XBiotech Inc.'s core focus is on discovering and developing True Human™ monoclonal antibodies, which are derived from human donors with natural immune responses. This approach is central to its strategy for both anti-inflammatory (IL-1a) and anti-infective therapies.
• Interleukin-1 Alpha (IL-1a) Therapies: Significant investment and strategic importance are placed on therapies that block IL-1a, a substance mediating tissue breakdown, angiogenesis, blood clot formation, and inflammation. The Company is developing multiple anti-IL-1a product candidates.
• Anti-Infective Antibodies: Focus on urgent unmet medical needs in infectious diseases, including MRSA, C. difficile, varicella zoster (shingles), and influenza. Innovation Pipeline: The Company's discovery process involves screening blood samples from healthy donors for exceptionally strong disease-fighting antibodies. XBiotech Inc. is actively developing new IL-1a targeting product candidates and has a clinical-stage therapeutic for MRSA, along with several pre-clinical stage anti-infective therapeutics.

Intellectual Property Portfolio:

• Patent Strategy: XBiotech Inc. relies on patent, trade secret, copyright, and trademark laws to protect its proprietary technology and products. The Company seeks to obtain and maintain patent protection in the U.S. and internationally.
• Licensing Programs: As part of the Janssen Transaction, Janssen Biotech, Inc. agreed to assert acquired IL-1a related patents for XBiotech Inc.'s benefit to protect its future non-dermatological IL-1a therapies. The Company also incurred increased patent filing expenses in 2024 due to the transfer of patents from Janssen Biotech, Inc. to XBiotech Inc.

Technology Partnerships:

• Strategic Alliances: Lonza Sales AG - Involved in a licensing agreement.
• Research Collaborations: South Texas Blood & Tissue Center - Engaged in a research and collaboration agreement.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The Company's future success is significantly dependent on the continued service of its Chief Executive Officer, John Simard, who is critical to strategic direction and R&D. Senior management members have an average tenure of over 12 years, providing deep institutional knowledge across antibody discovery, development, manufacturing, regulatory submissions, clinical trials, and commercial sale.

Board Composition: The Board of Directors is composed of individuals with significant industry, scientific, and legal knowledge. Key directors include John Simard, W. Thorpe McKenzie, Jan-Paul Waldin, Peter Libby, and Tak W. Mak.

Human Capital Strategy

Workforce Composition:

• Total Employees: 92 full-time employees as of December 31, 2024.
• Geographic Distribution: Primarily located in the U.S., with headquarters in Austin, Texas.
• Skill Mix: The Company's employees possess collective knowledge across antibody discovery, preclinical development, formulation, manufacturing, regulatory submissions, human clinical trials, and commercial sale. The number of R&D employees increased from 79 in 2023 to 89 in 2024.
• Labor Relations: None of the employees are represented by a collective bargaining agreement, and the Company has not experienced any work stoppages, indicating good employee relations.

Talent Management: Acquisition & Retention: XBiotech Inc. is committed to long-term growth and recognizes the competitive nature of the industry for experienced employees. Its compensation programs are designed to attract and retain talent, including competitive salaries, stock option awards (upon hiring and annually), and annual bonuses contingent on corporate and personal objectives. Employee Value Proposition: The Company aims to provide a strong employee value proposition through its compensation, leave, and benefits programs.

Diversity & Development: XBiotech Inc. has an Employee Handbook outlining corporate policies and guidelines for professional behavior, including a Code of Business Conduct and Ethics.

Regulatory Environment & Compliance

Regulatory Framework: The pharmaceutical and biotechnology industry is highly regulated at state, federal, and international levels. XBiotech Inc. must navigate complex regulatory approval processes from authorities such as the FDA and comparable foreign regulatory bodies (e.g., EMA), which are lengthy, time-consuming, and unpredictable. Regulatory policies, requirements, and the amount of clinical data needed for approval can change during a product candidate's development. Post-approval, products are subject to ongoing oversight governing manufacturing, quality control, labeling, promotion, and safety surveillance. Industry-Specific Regulations:

• Product Approval: Product candidates must demonstrate substantial evidence of safety and efficacy in preclinical and well-controlled clinical studies to gain regulatory approval.
• Manufacturing Compliance: Manufacturers and facilities are subject to continual review and periodic inspections for compliance with current good manufacturing practices (cGMP).
• Advertising & Promotion: The FDA strictly regulates drug product advertising and promotion, limiting it to approved uses consistent with labeling. Impermissible promotion of off-label uses can lead to false claims litigation and significant penalties.

Legal Proceedings: The Company is not currently subject to any material legal proceedings.

Tax Strategy & Considerations

Tax Profile: XBiotech Inc. incurred a net loss of $38.5 million in 2024 and $24.6 million in 2023. The Company's income tax benefit of $0.03 million in 2024 was primarily due to uncertain tax position activity and an estimated Canadian loss carryback to 2023. The effective tax rate for 2024 and 2023 varied from the Canadian statutory rate (27.0%) primarily due to losses in jurisdictions where a full valuation allowance is recorded. The Company expects to maintain a full valuation allowance on all jurisdictions during 2025.

• Geographic Tax Planning: The Company is subject to income tax in Canada, the USA, and the state of Texas.
• Tax Reform Impact: XBiotech Inc. has a USA federal net operating loss carryforward of $2.8 million (indefinite carryforward), USA federal research and development tax credits carryforwards of $9.2 million (expiring from 2037), and Texas research and development tax credits carryforwards of $12.7 million (expiring from 2042). The Company also has a Canada net operating loss carryforward of $12.3 million (expiring from 2044), excluding amounts expected to be carried back to 2023.
• Uncertain Tax Positions: As of December 31, 2024, the Company had $3.4 million in unrecognized tax benefits, with approximately $1.0 million reasonably possible to be recognized in the next 12 months due to the lapse of the statute of limitations.

Insurance & Risk Transfer

Risk Management Framework: XBiotech Inc. does not carry insurance for all categories of risk its business may encounter and is predominantly self-insured for business disruptions caused by natural disasters or public health threats.

• Insurance Coverage: The Company maintains insurance for employee injury related to hazardous materials but does not maintain insurance for environmental liability or toxic tort claims.
• Risk Transfer Mechanisms: XBiotech Inc. plans to obtain product liability insurance coverage upon obtaining marketing approval for its product candidates but acknowledges that commercially reasonable terms may not be available.